Bildiri Koleksiyonu
Güncel Gönderiler
-
The relationship between the change with neoadjuvant chemotherapy in the tumor-infiltrating lymphocyte (TIL) expressions and pathological response in breast cancer patients.
(Lippincott Williams & Wilkins, 2023)... -
Prospective real-world outcomes of acute myeloid leukemia
(American Society of Hematology, 2023)Background: It is evident that treatment outcomes improve with the clinical studies, in this study we aimed to investigate the demographics and treatment modalities of the acute myeloid leukemia (AML) patients in a large ... -
Idarubicin versus daunorubicin versus mitoxantrone for induction chemotherapy in acute myeloid leukemia: Patient registration study of Turkish society of hematologyacute myeloid leukemia working group
(American Society of Hematology, 2023)Introduction: Standard induction chemotherapy in newly diagnosed acute myeloid leukemia (AML) includes a combination of standard-dose cytarabine and an anthracycline (idarubicin [IDA], daunorubicin [DNR], or mitoxantrone ... -
Acute myeloid leukemia in elderly, unfit patients: Analysis of Turkish AML prospective registry database, on behalf of acute leukemia working group of Turkish society of hematology
(American Society of Hematology, 2023)Objective: Low dose Ara-C and hypomethylating agents (HMAs) - decitabine (DEC) and azacitidine (AZA) - have made it possible to treat more elderly patients with acute myeloid leukemia (AML). Both HMAs demonstrated efficacy ... -
Open-label, randomized, phase 3 study of coformulated favezelimab and pembrolizumab versus chemotherapy in patients with relapsed or refractory classical hodgkin lymphoma refractory to anti-PD-1 therapy: Keyform-008
(American Society of Hematology, 2023)Background: The importance of PD-1 therapy in relapsed or refractory (R/R) classical Hodgkin Lymphoma (cHL) is well established, with PD-1 inhibitors such as pembrolizumab being a standard of care option for patients. ... -
Comparison of the effectiveness of the personalized schroth exercise and conventional therapy for scoliosis in children with rheumatic disease
(BMJ Publishing Group, 2023)Background: Childhood rheumatic disease is one of the most common chronic diseases in childhood and adolescence [1]. In particular, it causes weakness, pain, problems in the musculoskeletal system, displacement of the ... -
Long-term course of COVID-19 vaccination-related headache: A prospective multicenter follow-up study
(SAGE Publications Ltd, 2023)... -
Real-life experiences with galcanezumab disclosed new predictors for response
(SAGE Publications Ltd, 2023)... -
KEYFORM-008: Coformulated favezelimab and pembrolizumab (MK4280A) versus chemotherapy in relapsed/refractory classical Hodgkin lymphoma.
(Lippincott Williams & Wilkins, 2023)... -
Modulatory therapy experience in patients with cystic fibrosis in Turkey: A multi-center study
(European Respiratory Society Journals Ltd., 2023)Background: Modulatory therapies are not reimbursed in Turkey and approach to the treatment is currently available for three months only by court decision. In between the court decisions, most of the patients could not ... -
Development and internal-external validation of a prediction model for premature ventricular contraction unresponsive to the medical treatment
(Oxford University Press, 2023)... -
Clinical assessment of HRD scoring in relation to PARPi response in terms of statistical guidance on reporting results for CDx tests evaluation.
(Lippincott Williams & Wilkins, 2023)... -
Plerixafor in autologous stem cell transplantation: Does it affect engraftment kinetics?
(Springer Nature, 2023)...